Russell Investments Group
FDMT icon

Russell Investments Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Russell Investments Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3K Sell
3,143
-267
-8% -$2.32K ﹤0.01% 3499
2025
Q4 		$25.6K Hold
3,410
– – ﹤0.01% 3541
2025
Q3 		$29.6K Sell
3,410
-18,406
-84% -$110K ﹤0.01% 3469
2025
Q2 		$80.9K Buy
21,816
+2,284
+12% +$8.03K ﹤0.01% 2875
2025
Q1 		$63.1K Buy
+19,532
New +$92K ﹤0.01% 2852
2024
Q4 		– Sell
-175
Closed -$1.89K – 3729
2024
Q3 		$1.89K Sell
175
-2,133
-92% -$35.4K ﹤0.01% 3384
2024
Q2 		$48.4K Buy
+2,308
New +$57.9K ﹤0.01% 2770
2023
Q4 		– Sell
-16
Closed -$204 – 3238
2023
Q3 		$204 Sell
16
-1,110
-99% -$18.6K ﹤0.01% 3495
2023
Q2 		$20.3K Hold
1,126
– – ﹤0.01% 2838
2023
Q1 		$19.4K Sell
1,126
-443
-28% -$8.61K ﹤0.01% 2817
2022
Q4 		$34.8K Hold
1,569
– – ﹤0.01% 2759
2022
Q3 		$12K Buy
+1,569
New +$14.2K ﹤0.01% 2849
2022
Q2 		– Sell
-742
Closed -$11K – 2914
2022
Q1 		$11K Sell
742
-56,197
-99% -$883K ﹤0.01% 2705
2021
Q4 		$1.25M Sell
56,939
-45,778
-45% -$1.12M ﹤0.01% 2041
2021
Q3 		$2.77M Buy
+102,717
New +$2.93M ﹤0.01% 1633

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Russell Investments Group's FDMT Position: Q1 2026 in Review

Russell Investments Group reduced its 4D Molecular Therapeutics (FDMT) stake by 7.8% in Q1 2026, selling an estimated $2.32K and leaving 3,143 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3499.

Russell Investments Group first reported a position in FDMT in Q3 2021 and has held it in 15 quarters since. The position peaked at $2.77M in Q3 2021. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Russell Investments Group held 3,143 shares of 4D Molecular Therapeutics worth $29.3K as of Q1 2026.
  • Russell Investments Group sold 267 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.32K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3499 holding.
  • Russell Investments Group first reported a position in 4D Molecular Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • Russell Investments Group's 4D Molecular Therapeutics position peaked at $2.77M in Q3 2021.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.